Foundry Healthcare Gross Margin Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1RPRX | ROYALTY PHARMA PLC | Healthcare | $33.50B | 13.68% |
2NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $17.18B | 7.02% |
3THC | TENET HEALTHCARE CORP | Healthcare | $16.79B | 6.86% |
4EXEL | EXELIXIS INC | Healthcare | $14.06B | 5.74% |
5ARWR | ARROWHEAD PHARMACEUTICALS INC | Healthcare | $10.47B | 4.27% |
6CYTK | CYTOKINETICS INC | Healthcare | $9.98B | 4.08% |
7CORT | CORCEPT THERAPEUTICS INC | Healthcare | $9.72B | 3.97% |
8KYMR | KYMERA THERAPEUTICS INC | Healthcare | $9.52B | 3.89% |
9PTGX | PROTAGONIST THERAPEUTICS INC | Healthcare | $9.06B | 3.70% |
10IONS | IONIS PHARMACEUTICALS INC | Healthcare | $8.99B | 3.67% |
11IBRX | IMMUNITYBIO INC | Healthcare | $8.04B | 3.29% |
12DNTH | DIANTHUS THERAPEUTICS INC | Healthcare | $5.77B | 2.36% |
13TVTX | TRAVERE THERAPEUTICS INC | Healthcare | $5.27B | 2.15% |
14CRSP | CRISPR THERAPEUTICS AG | Healthcare | $4.61B | 1.88% |
15TNGX | TANGO THERAPEUTICS INC | Healthcare | $4.13B | 1.69% |
16RLAY | RELAY THERAPEUTICS INC | Healthcare | $3.81B | 1.56% |
17ALMS | ALUMIS INC | Healthcare | $3.65B | 1.49% |
18NHC | NATIONAL HEALTHCARE CORP | Healthcare | $3.56B | 1.46% |
19RCUS | ARCUS BIOSCIENCES INC | Healthcare | $3.44B | 1.41% |
20IDYA | IDEAYA BIOSCIENCES INC | Healthcare | $3.16B | 1.29% |
21BEAM | BEAM THERAPEUTICS INC | Healthcare | $2.83B | 1.16% |
22CLDX | CELLDEX THERAPEUTICS INC | Healthcare | $2.77B | 1.13% |
23ATAI | ATAIBECKLEY INC | Healthcare | $2.66B | 1.09% |
24IMNM | IMMUNOME INC | Healthcare | $2.53B | 1.03% |
25NRIX | NURIX THERAPEUTICS INC | Healthcare | $2.40B | 0.98% |
26BCRX | BIOCRYST PHARMACEUTICALS INC | Healthcare | $2.36B | 0.96% |
27NKTR | NEKTAR THERAPEUTICS | Healthcare | $2.31B | 0.94% |
28GLUE | MONTE ROSA THERAPEUTICS INC | Healthcare | $2.07B | 0.85% |
29RAPP | RAPPORT THERAPEUTICS INC | Healthcare | $2.04B | 0.83% |
30SNDX | SYNDAX PHARMACEUTICALS INC | Healthcare | $2.02B | 0.83% |
31ABCL | ABCELLERA BIOLOGICS INC | Healthcare | $1.97B | 0.81% |
32VRDN | VIRIDIAN THERAPEUTICS INC | Healthcare | $1.86B | 0.76% |
33STOK | STOKE THERAPEUTICS INC | Healthcare | $1.81B | 0.74% |
34IMCR | IMMUNOCORE HOLDINGS PLC | Healthcare | $1.78B | 0.73% |
35ZYME | ZYMEWORKS INC | Healthcare | $1.77B | 0.72% |
36TSHA | TAYSHA GENE THERAPIES INC | Healthcare | $1.71B | 0.70% |
37ANAB | ANAPTYSBIO INC | Healthcare | $1.69B | 0.69% |
38VIR | VIR BIOTECHNOLOGY INC | Healthcare | $1.59B | 0.65% |
39NTLA | INTELLIA THERAPEUTICS INC | Healthcare | $1.59B | 0.65% |
40MAZE | MAZE THERAPEUTICS INC | Healthcare | $1.56B | 0.64% |
41SEPN | SEPTERNA INC | Healthcare | $1.51B | 0.61% |
42XNCR | XENCOR INC | Healthcare | $1.30B | 0.53% |
43ABSI | ABSCI CORP | Healthcare | $1.29B | 0.53% |
44INBX | INHIBRX BIOSCIENCES INC | Healthcare | $1.28B | 0.52% |
45WVE | WAVE LIFE SCIENCES LTD | Healthcare | $1.12B | 0.46% |
46AVTX | AVALO THERAPEUTICS INC | Healthcare | $1.02B | 0.42% |
47BIOA | BIOAGE LABS INC | Healthcare | $1.01B | 0.41% |
48JANX | JANUX THERAPEUTICS INC | Healthcare | $992M | 0.41% |
49KURA | KURA ONCOLOGY INC | Healthcare | $964M | 0.39% |
50TBPH | THERAVANCE BIOPHARMA INC | Healthcare | $873M | 0.36% |
51STTK | SHATTUCK LABS INC | Healthcare | $577M | 0.24% |
52FDMT | 4D MOLECULAR THERAPEUTICS INC | Healthcare | $575M | 0.23% |
53ARVN | ARVINAS INC | Healthcare | $517M | 0.21% |
54XOMA | XOMA ROYALTY CORP | Healthcare | $504M | 0.21% |
55PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $453M | 0.19% |
56CBIO | CRESCENT BIOPHARMA INC | Healthcare | $407M | 0.17% |
57ENTA | ENANTA PHARMACEUTICALS INC | Healthcare | $400M | 0.16% |
58STRO | SUTRO BIOPHARMA INC | Healthcare | $391M | 0.16% |
59UPB | UPSTREAM BIO INC | Healthcare | $382M | 0.16% |
60LYEL | LYELL IMMUNOPHARMA INC | Healthcare | $311M | 0.13% |
61FHTX | FOGHORN THERAPEUTICS INC | Healthcare | $305M | 0.12% |
62TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $268M | 0.11% |
63QTTB | Q32 BIO INC | Healthcare | $255M | 0.10% |
64SRZN | SURROZEN INC | Healthcare | $255M | 0.10% |
65RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $243M | 0.10% |
66KROS | KEROS THERAPEUTICS INC | Healthcare | $211M | 0.09% |
67AGEN | AGENUS INC | Healthcare | $209M | 0.09% |
68DTIL | PRECISION BIOSCIENCES INC | Healthcare | $203M | 0.08% |
69KRRO | KORRO BIO INC | Healthcare | $177M | 0.07% |
70ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $172M | 0.07% |
71VTVT | VTV THERAPEUTICS INC | Healthcare | $130M | 0.05% |
72CUE | CUE BIOPHARMA INC | Healthcare | $126M | 0.05% |
73RLYB | RALLYBIO CORP | Healthcare | $87M | 0.04% |
74FRMM | FORUM MARKETS INC | Healthcare | $83M | 0.03% |
75ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $76M | 0.03% |
76XLO | XILIO THERAPEUTICS INC | Healthcare | $53M | 0.02% |
77MCRB | SERES THERAPEUTICS INC | Healthcare | $52M | 0.02% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $244.82B. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 83% toward Large, 52% toward Growth. +12% unclassified (10 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 77 names now. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 77 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators disagree about the verdict, not just the value — the choice of method decides the answer here. Historical VaR gives ratio 1.87 (pass) but Gaussian VaR gives 2.08 (fail). The pass/fail conclusion is an artefact of estimator choice, not a property of the strategy.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Publication date unknown. We don’t have a source year for this signal, so we can’t split its record into before and since publication. That’s a gap in our reference data — not a statement about how the factor performed.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 78.4% | 24.7% |
| 3 yearsp.a. | 25.4% | 20.9% |
| 5 yearsp.a. | 5.3% | 1.0% |
| 10 yearsp.a. | 16.5% | 6.3% |
| Since inceptionp.a. | 14.1% | 3.0% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 25.8% | 8.0% |
| 2025 | 52.0% | 48.1% |
| 2024 | -7.3% | 1.2% |
| 2023 | 17.8% | 15.4% |
| 2022 | -33.3% | -31.5% |
| 2021 | -9.7% | -34.0% |
| 2020 | 83.8% | 62.3% |
| 2019 | 71.1% | 44.7% |
| 2018 | -5.7% | -10.3% |
| 2017 | 44.9% | 17.3% |
| 2016 | -32.6% | -29.3% |
| 2015 | 2.4% | -4.8% |
| 2014 | 21.5% | -5.3% |
| 2013 | 65.4% | 14.3% |
| 2012 | 40.7% | 23.7% |
| 2011 | 4.8% | -11.2% |
| 2010 | 23.1% | 8.3% |
| 2009 | 16.0% | -12.1% |
| 2008 | 0.9% | 67.5% |
| 2007 | -11.6% | -24.5% |
| 2006 | -2.4% | -1.4% |
| 2005 | 8.4% | -18.4% |
| 2004 | 8.2% | -16.8% |
| 2003 | 28.7% | -4.7% |
| 2002 | -39.1% | -31.3% |
| 2001 | -14.3% | -8.0% |
| 2000 | 66.5% | -1.0% |
| 1999 | 113.3% | 183.5% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare Gross Margin Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Gross Margin signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.